Baxter International Inc. 10-K Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2006. Baxter International Inc. is a global diversified medical products and services company operating in three primary segments: BioScience (plasma-based and recombinant proteins), Medication Delivery (IV solutions and administration sets), and Renal (dialysis products). The company manufactures in 28 countries and sells in over 100 countries, with more than 50% of revenues generated outside the United States. As of December 31, 2006, the company employed approximately 48,000 people.
Key Financial Metrics
The filing text incorporates detailed financial statements by reference and does not provide specific consolidated revenue, net income, or cash flow totals for the year. However, the following specific financial data points are disclosed:
- Research and Development (R&D): Expenditures for continuing operations were $614 million in 2006, compared to $533 million in 2005.
- Stock Repurchases: In the fourth quarter of 2006, the company repurchased approximately 5.6 million shares for $258 million. The remaining authorization under the program was approximately $1 billion as of year-end.
- Market Value: The aggregate market value of voting common equity held by non-affiliates was approximately $24.0 billion as of June 30, 2006.
- Valuation Reserves (Schedule II):
- Allowance for doubtful accounts: $127 million (end of period).
- Inventory reserves: $180 million (end of period).
- Deferred tax asset valuation allowance: $234 million (end of period).
Specific figures for total debt, liquidity ratios, and operating margins are not explicitly stated in the provided text.
Material Changes and Transactions
- Divestiture of Transfusion Therapies (TT): On October 2, 2006, Baxter entered into a definitive agreement to sell substantially all assets and liabilities of its Transfusion Therapies business (part of BioScience) to an affiliate of Texas Pacific Group (TPG) for $540 million. The sale was expected to close in the first quarter of 2007.
- Leadership Changes: Robert M. Davis was appointed Corporate Vice President and Chief Financial Officer in May 2006. Michael J. Baughman was appointed Corporate Vice President and Controller in May 2006.
- Regulatory Consent Decree: The company is subject to a Consent Decree with the U.S. government regarding its COLLEAGUE and SYNDEO infusion pumps, requiring ongoing compliance and potential sanctions.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The company emphasizes global expansion and technological innovation. Strategic R&D focus areas include recombinant therapeutics, adult stem-cell therapy, and biosurgery products. Management notes that healthcare cost containment continues to exert pressure on product pricing globally.
Key Risks and Contingencies:
- Regulatory and Quality Issues: Ongoing issues with infusion pumps (COLLEAGUE Matter) pose risks of additional charges, sanctions, or loss of customer confidence. The company faces extensive regulation by the FDA and international agencies.
- Reimbursement Pressure: Sales depend on reimbursement by government agencies and private payers. Legislation or policy changes reducing reimbursement rates could negatively impact operating results.
- Intellectual Property: The company is susceptible to patent litigation, which could result in significant royalty payments or injunctions preventing product sales.
- Global Operations: Risks include foreign currency fluctuations, political instability, and compliance with varying international laws.
- Legal Proceedings: The company is involved in various legal actions. While specific reserves are not detailed in the text, management notes that resolution of certain matters could result in charges in excess of established reserves.
Investor Verification Checklist
- Verify the closing status and final proceeds of the $540 million Transfusion Therapies sale in Q1 2007 filings.
- Review the Annual Report to Shareholders (incorporated by reference) for full consolidated revenue, net income, and cash flow statements not detailed in this text.
- Monitor updates on the COLLEAGUE infusion pump Consent Decree for any new FDA sanctions or additional financial charges.
- Assess the impact of reimbursement policy changes in key international markets on future pricing power.
- Confirm the status of patent litigation outcomes that could affect core product lines in BioScience and Medication Delivery.